The Francisella tularensis FabI enoyl-acyl carrier protein reductase gene is essential to bacterial viability and is expressed during infection

Journal of Bacteriology

Volumn 195, Issue 2, 2013, Pages 351-358

  Kingry, Luke C ^a,c   Cummings, Jason E ^a   Brookman, Kerry W ^a   Bommineni, Gopal R ^b   Tonge, Peter J ^b   Slayden, Richard A ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL RNA; CERULENIN; DISINFECTANT AGENT; FABI ENOYL ACYL CARRIER PROTEIN REDUCTASE; OXIDOREDUCTASE; SBPT 04; THIOLACTOMYCIN; TRICLOSAN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL VIABILITY; DNA MICROARRAY; DRUG TARGETING; ENZYME INHIBITION; FATTY ACID SYNTHESIS; FRANCISELLA TULARENSIS; GENE FUNCTION; GENE LOCUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ANIMALS; DISEASE MODELS, ANIMAL; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); FATTY ACIDS; FRANCISELLA TULARENSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, BACTERIAL; GENES, BACTERIAL; GENES, ESSENTIAL; HUMANS; MICE; MICROARRAY ANALYSIS; MICROBIAL VIABILITY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TULAREMIA;

BACTERIA (MICROORGANISMS); FRANCISELLA; FRANCISELLA TULARENSIS;

EID: 84872146824     PISSN: 00219193     EISSN: 10985530     Source Type: Journal    
DOI: 10.1128/JB.01957-12     Document Type: Article

References (39)

1. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Layton M, Lillibridge SR, McDade JE, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Tonat K. 2001. Tularemia as a biological weapon: medical and public health management. JAMA 285:2763-2773.
2. Miller SD, Snyder MB, Kleerekoper M, Grossman CH. 1989. Ulceroglandular tularemia: a typical case of relapse. Henry Ford Hosp. Med. J. 37:73-75.
3. Penn RL, Kinasewitz GT. 1987. Factors associated with a poor outcome in tularemia. Arch. Intern. Med. 147:265-268.
4. England K, Am Ende C, Lu H, Sullivan TJ, Marlenee NL, Bowen RA, Knudson SE, Knudson DL, Tonge PJ, Slayden RA. 2009. Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia. J. Antimicrob. Chemother. 64:1052-1061.
5. Liu N, Cummings JE, England K, Slayden RA, Tonge PJ. 2011. Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei. J. Antimicrob. Chemother. 66:564-573.
6. Lu H, England K, am Ende C, Truglio JJ, Luckner S, Reddy BG, Marlenee NL, Knudson SE, Knudson DL, Bowen RA, Kisker C, Slayden RA, Tonge PJ. 2009. Slow-onset inhibition of the FabI enoyl reductase from Francisella tularensis: residence time and in vivo activity. ACS Chem. Biol. 4:221-231.
7. Brinster S, Lamberet G, Staels B, Trieu-Cuot P, Gruss A, Poyart C. 2009. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature 458:83-86.
8. Balemans W, Lounis N, Gilissen R, Guillemont J, Simmen K, Andries K, Koul A. 2010. Essentiality of FASII pathway for Staphylococcus aureus. Nature 463:E3. doi:10.1038/nature08667.
9. Parsons JB, Frank MW, Subramanian C, Saenkham P, Rock CO. 2011. Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors. Proc. Natl. Acad. Sci. U.S.A. 108: 15378-15383.
10. Schiebel J, Chang A, Lu H, Baxter MV, Tonge PJ, Kisker C. 2012. Staphylococcus aureus FabI: inhibition, substrate recognition, and potential implications for in vivo essentiality. Structure 20:802-813.
11. Nichols PD, Mayberry WR, Antworth CP, White DC. 1985. Determination of monounsaturated double-bond position and geometry in the cellular fatty acids of the pathogenic bacterium Francisella tularensis. J. Clin. Microbiol. 21:738-740.
12. Phillips NJ, Schilling B, McLendon MK, Apicella MA, Gibson BW. 2004. Novel modification of lipid A of Francisella tularensis. Infect. Immun. 72:5340-5348.
13. LoVullo ED, Molins-Schneekloth CR, Schweizer HP, Pavelka MS, Jr. 2009. Single-copy chromosomal integration systems for Francisella tularensis. Microbiology 155:1152-1163.
14. Bergler H, Hogenauer G, Turnowsky F. 1992. Sequences of the envM gene and of two mutated alleles in Escherichia coli. J. Gen. Microbiol. 138:2093-2100.
15. Mdluli K, Slayden RA, Zhu Y, Ramaswamy S, Pan X, Mead D, Crane DD, Musser JM, Barry CE, III. 1998. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science 280:1607-1610.
16. Miller WH, Seefeld MA, Newlander KA, Uzinskas IN, Burgess WJ, Heerding DA, Yuan CC, Head MS, Payne DJ, Rittenhouse SF, Moore TD, Pearson SC, Berry V, DeWolf WE, Jr, Keller PM, Polizzi BJ, Qiu X, Janson CA, Huffman WF. 2002. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J. Med. Chem. 45:3246-3256.
17. Park HS, Yoon YM, Jung SJ, Kim CM, Kim JM, Kwak JH. 2007. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. J. Antimicrob. Chemother. 60: 568-574.
18. Ramnauth J, Surman MD, Sampson PB, Forrest B, Wilson J, Freeman E, Manning DD, Martin F, Toro A, Domagala M, Awrey DE, Bardouniotis E, Kaplan N, Berman J, Pauls HW. 2009. 2,3,4,5-Tetrahydro-1Hpyrido[ 2,3-b and e][1,4]diazepines as inhibitors of the bacterial enoyl ACP reductase, FabI. Bioorg. Med. Chem. Lett. 19:5359-5362.
19. Seefeld MA, Miller WH, Newlander KA, Burgess WJ, DeWolf WE, Jr, Elkins PA, Head MS, Jakas DR, Janson CA, Keller PM, Manley PJ, Moore TD, Payne DJ, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Uzinskas IN, Wallis NG, Huffman WF. 2003. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. J. Med. Chem. 46:1627-1635.
20. Luckner SR, Liu N, am Ende CW, Tonge PJ, Kisker C. 2010. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis. J. Biol. Chem. 285:14330-14337.
21. Sullivan TJ, Truglio JJ, Boyne ME, Novichenok P, Zhang X, Stratton CF, Li H-J, Kaur T, Amin A, Johnson F, Slayden RA, Kisker C, Tonge PJ. 2006. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem. Biol. 1:43-53.
22. Xu H, Sullivan TJ, Sekiguchi J, Kirikae T, Ojima I, Mao W, Rock FL, Alley MRK, Johnson F, Walker SG, Tonge PJ. 2008. Mechanism and inhibition of saFabI, the enoyl reductase from Staphylococcus aureus. Biochemistry 47:4228-4236.
23. Slayden RA, Lee RE, Barry CE III. 2000. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Mol. Microbiol. 38:514-525.
24. Kingry LC, Troyer RM, Marlenee NL, Bielefeldt-Ohmann H, Bowen RA, Schenkel AR, Dow SW, Slayden RA. 2011. Genetic identification of unique immunological responses in mice infected with virulent and attenuated Francisella tularensis. Microbes Infect. 13:261-275.
25. Heath RJ, Rubin JR, Holland DR, Zhang E, Snow ME, Rock CO. 1999. Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J. Biol. Chem. 274:11110-11114.
26. Heath RJ, White SW, Rock CO. 2002. Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics. Appl. Microbiol. Biotechnol. 58:695-703.
27. Heath RJ, Yu YT, Shapiro MA, Olson E, Rock CO. 1998. Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis. J. Biol. Chem. 273:30316-30320.
28. Lu H, Tonge PJ. 2008. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. Acc. Chem. Res. 41:11-20.
29. McMurry LM, McDermott PF, Levy SB. 1999. Genetic evidence that InhA of Mycobacterium smegmatis is a target for triclosan. Antimicrob. Agents Chemother. 43:711-713.
30. Stewart MJ, Parikh S, Xiao G, Tonge PJ, Kisker C. 1999. Structural basis and mechanism of enoyl reductase inhibition by triclosan. J. Mol. Biol. 290:859-865.
31. Ward WH, Holdgate GA, Rowsell S, McLean EG, Pauptit RA, Clayton E, Nichols WW, Colls JG, Minshull CA, Jude DA, Mistry A, Timms D, Camble R, Hales NJ, Britton CJ, Taylor IW. 1999. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry 38:12514-12525.
32. Boyne ME, Sullivan TJ, am Ende CW, Lu H, Gruppo V, Heaslip D, Amin AG, Chatterjee D, Lenaerts A, Tonge PJ, Slayden RA. 2007. Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ringmodified diphenyl ethers as high-affinity InhA inhibitors. Antimicrob. Agents Chemother. 51:3562-3567.
33. Gallagher LA, Ramage E, Jacobs MA, Kaul R, Brittnacher M, Manoil C. 2007. A comprehensive transposon mutant library of Francisella novicida, a bioweapon surrogate. Proc. Natl. Acad. Sci. U.S.A. 104:1009-1014.
34. Kawula TH, Hall JD, Fuller JR, Craven RR. 2004. Use of transposontransposase complexes to create stable insertion mutant strains of Francisella tularensis LVS. Appl. Environ. Microbiol. 70:6901-6904.
35. Maier TM, Casey MS, Becker RH, Dorsey CW, Glass EM, Maltsev N, Zahrt TC, Frank DW. 2007. Identification of Francisella tularensis Himar1-based transposon mutants defective for replication in macrophages. Infect. Immun. 75:5376-5389.
36. Maier TM, Pechous R, Casey M, Zahrt TC, Frank DW. 2006. In vivo Himar1-based transposon mutagenesis of Francisella tularensis. Appl. Environ. Microbiol. 72:1878-1885.
37. Qin A, Mann BJ. 2006. Identification of transposon insertion mutants of Francisella tularensis tularensis strainSchuS4 deficient in intracellular replication in the hepatic cell line HepG2.BMCMicrobiol. 6:69. doi:10.1186/1471-2180-6-69.
38. Schulert GS, McCaffrey RL, Buchan BW, Lindemann SR, Hollenback C, Jones BD, Allen LA. 2009. Francisella tularensis genes required for inhibition of the neutrophil respiratory burst and intramacrophage growth identified by random transposon mutagenesis of strain LVS. Infect. Immun. 77:1324-1336.
39. Tempel R, Lai XH, Crosa L, Kozlowicz B, Heffron F. 2006. Attenuated Francisella novicida transposon mutants protect mice against wild-type challenge. Infect. Immun. 74:5095-5105.